Entinostat
- Generic Name
- Entinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20N4O3
- CAS Number
- 209783-80-2
- Unique Ingredient Identifier
- 1ZNY4FKK9H
- Background
Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.
- Indication
联合芳香化酶抑制剂用于治疗激素受体（HR）阳性、人类表皮生长因子受体-2（HER-2）阴性，经内分泌治疗复发或进展的局部晚期或转移性乳腺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
- Conditions
- Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myelomonocytic Leukemia (M4)Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT01159301
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT01132573
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT01105377
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT01038778
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT00866333
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
- Conditions
- Interventions
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT00828854
- Locations
- 🇬🇧
University College London Hospitals, London, United Kingdom
🇬🇧Christie Hospital, Manchester Breast Centre, Manchester, United Kingdom
🇬🇧Velindre Hospital - Whitchurch, Cardiff, United Kingdom
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT00750698
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Sharp Clinical Oncology Research, San Diego, California, United States
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT00676663
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Memorial Cancer Institute, Hollywood, Florida, United States
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 141
- Registration Number
- NCT00602030
- Locations
- 🇺🇸
Fairfax Northern Virginia Hematology-Oncology, Fairfax, Virginia, United States
🇺🇸HOPE (Hematology Oncology Physicians & Extenders), Tucson, Arizona, United States
🇺🇸Oncology Associates of Oregon, Eugene, Oregon, United States
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
- Conditions
- Adult Acute Myeloblastic Leukemia With Maturation (M2)Untreated Adult Acute Myeloid LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Erythroleukemia (M6a)de Novo Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00462605
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.